← Back to Clinical Trials
Recruiting NCT04817566

NCT04817566 Cognitive Training and Brain Stimulation in Women With Post-chemotherapy Cognitive Impairment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04817566
Status Recruiting
Phase
Sponsor University Medicine Greifswald
Condition Breast Cancer
Study Type INTERVENTIONAL
Enrollment 52 participants
Start Date 2021-11-02
Primary Completion 2026-06

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Anodal tDCSSham tDCSIntensive cognitive training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 52 participants in total. It began in 2021-11-02 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to investigate whether a high definition tDCS-accompanied intensive cognitive training of working memory leads to performance improvement in women with post-chemotherapy cognitive impairment after breast cancer treatment.

Eligibility Criteria

Inclusion Criteria: 1. Chemotherapy to treat breast cancer (≥ 6 months post-treatment). 2. Self-reported concerns regarding cognitive functioning. 3. Age: 18-65 years. 4. right-handedness Exclusion Criteria: 1. History of dementia before treatment of cancer. 2. Other neurodegenerative neurological disorders; epilepsy or history of seizures. 3. Severe and untreated medical conditions that preclude participation in the training, as determined by responsible physician. 4. History of moderate to severe substance use disorder according to DSM-5 5. Moderate to severe acute psychiatric disorders according to DSM-5 6. Contraindication to tDCS application (Antal et al., 2017)

Contact & Investigator

Central Contact

Agnes Flöel, Prof.

✉ agnes.floeel@med.uni-greifswald.de

📞 0049 3834 86 6815

Principal Investigator

Agnes Flöel, Prof.

STUDY DIRECTOR

University Medicine Greifswald

Frequently Asked Questions

Who can join the NCT04817566 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 65 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04817566 currently recruiting?

Yes, NCT04817566 is actively recruiting participants. Contact the research team at agnes.floeel@med.uni-greifswald.de for enrollment information.

Where is the NCT04817566 trial being conducted?

This trial is being conducted at Greifswald, Germany.

Who is sponsoring the NCT04817566 clinical trial?

NCT04817566 is sponsored by University Medicine Greifswald. The principal investigator is Agnes Flöel, Prof. at University Medicine Greifswald. The trial plans to enroll 52 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology